Among them, blocking the CSF1-CSF1R signaling pathway can not only reduce the recruitment and differentiation of TAMs, but also promote the reprogramming of TAMs to the anti-tumor type, thereby enhancing the anti-tumor immune response (68, 94, 99). Here, CSF1R is linked to neoplasm.